News

One study seeks to understand the underlying causes of racial and ethnic disparities in cancer survival. The results may be surprising.

The success of any value-based care model depends on achieving a strong relationship with members. Here’s three ways how.

While many analyses of Section 1a of the executive order cite doom and gloom for health plans, four tenuous contingencies all must take place in order for this to occur.

FDA approved a new once-weekly, single-dose autoinjector device to improve glycemic control in adults with type 2 diabetes.

Payers’ biggest concerns for 2018, health insurance exchange participation plans, and how offerings could change.

A new study has unbelievable findings about treating Medicare patients with diabetes.

A Robert Wood Johnson Foundation expert analyzes the Altarum Institute’s study on healthcare growth findings.

As genomics continues to evolve, here are five things to know about genetic testing and counseling.

A survey explores how physicians perceive their role in the healthcare system, and the findings aren’t good.

FDA incentives have hastened the development of “orphan drugs” for rare diseases, but some worry that regulators are not always demanding clear evidence for drug efficacy.

With the high efficacy and dire diagnosis, there will be demand for both Kymriah and Yescarta. Here’s how to manage the monetary impact.

CAR-T therapies have high price tags so it’s important to understand your patient population and budget impact.

A University of Massachusetts clinical consulting pharmacist shows how assessing budget implications can be accomplished.

CMS’ 5-Star Rating system requires proactive intervention to improve patient medication adherence, and leaves plans with little room to rest on their laurels.

Pre-drug-approval forecasting and budgeting is increasingly important for payers. Is a safe harbor for manufacturers necessary?

External, non-payer generated data can inform formulary decision-making-if payers know their strengths and weaknesses.

New Yale University research offers stunning findings about drug formulary coverage and prescribing opioids.

One expert says incentive programs to motivate physicians miss the mark. Here’s what he recommends instead.

As the healthcare system shifts from a focus on employee-based plans to consumer-based plans, insurers have to find new ways to engage and motivate members.

Providers are coming up short when it comes to HEDIS measures related to substance abuse. Here’s how one health plan is changing that.

The specialty drugs market will see more approvals in 2017 than 2016. Top areas to watch include cancer, multiple sclerosis, and HIV.

Value-based insurance designs for diabetes care improve outcomes, but monetary gains may take years.

Recent and pending drug approvals emphasize the growing importance of niche agents for very specific cancer patient populations.

Avalere Health analysis has intriguing results about beneficiaries enrolled in diabetes-focused chronic condition special needs plans.

FDA Commissioner Scott Gottlieb, MD, said that the United States is likely to see shortages on certain drugs because after Hurricanes Irma and Maria knocked out power to the islands.

Why researchers say the industry is “a long way off” from robust electronic patient data sharing.

Trump takes two steps to dissolve the ACA. Find out what the experts think about these two important actions.

Here’s a quick guide to the meaning behind Trump’s executive order and decision to stop cost-sharing reduction payments.